Bioseparation Products for Drug Purification
Our bioseparation technologies are used in a variety of applications for the production and purification of biopharmaceuticals, for the capture and removal of biocontaminants or to extract and recover valuable proteins from various sources. This is a process commonly known as “affinity chromatography”. This process is mainly used for the separation and isolation of proteins. The technique relies upon the ability of proteins to recognize and bind to target biomolecules (ligands) in a specific and reversible manner. Affinity chromatography uses an adsorbent comprised of a porous support matrix to which the ligand is attached. An affinity separation is then performed by passing the protein solution over the adsorbent, incorporating the ligand, so that the target protein is adsorbed while allowing contaminants (other proteins, lipids, carbohydrates, DNA, pigments, etc.) to pass through without hindrance. The adsorbent is normally contained within a chromatography column. Following adsorption, the adsorbent is washed with buffer to remove residual contaminants and then the bound protein is eluted in pure form.
Our proprietary affinity adsorbents are manufactured in our UK based subsidiary (Isle of Man), ProMetic BioSciences Ltd (“PBL”). They are sold to and used by some of the most reputable biopharmaceutical companies in the world in their respective drugs manufacturing processes. Through years of research and development, PBL has built an extensive ligand library and now offers ligands targeting a vast selection of proteins. PBL has experienced continued revenue growth and profitability since 2007. In 2012, PBL solidly contributed to the growth and increased profitability of the Corporation by shipping products for more than $11.5 million compared to $5.2 million in 2011.
With more than 28 commercial applications and products currently under development and more than 14 applications and products already approved utilizing ProMetic’s technologies, PBL’s growing stream of recurring revenues is expected to achieve critical mass status and play an important role in the overall growth and profitability objectives of the Corporation in the coming years.
How it works (WMV -393 kb)
For global support for bioseparation solutions contacts: please click here
For more information, please contact us.